Introduction
============

Hepatoblastoma is one of the major malignant tumors in children and originates from the progenitor cell during embryogenesis, accounting for two-thirds of the pediatric malignant tumors [@B1]. The incidence rate is approximately 1.5 cases/million population per year (around 1% of cancers for young children) [@B2] and has been rising 4% per year continually [@B3]. This phenomenon is partly due to increased prematurity and very low birth weight [@B4],[@B5]. The development of hepatoblastoma is also associated with some environmental factors, such as parental exposure to tobacco, metal and petroleum products [@B6]-[@B9]. Moreover, it is strongly associated with familial adenomatous polyposis [@B10], Beckwith-Wiedemann syndrome [@B11], and Glycogen storage disease [@B12], indicating some genetic underpinnings. Although progressive surgical techniques and chemotherapy regimens have increased survival rates, the prognosis of high-risk hepatoblastoma remains very poor [@B13]. As for the molecular mechanism, although Wnt/β-catenin, MYC, and Hippo pathways have been reported to be involved in the pathogenesis of hepatoblastoma [@B14]-[@B16], little is known about the molecular basis of this disease, and there are no validated prognostic or therapeutic biomarkers for hepatoblastoma patients.

*LIN28B* gene encodes an RNA-binding protein, which is featured by the conservative N-terminal cold-shock domain and two C-terminal CysCysHisCys zinc fingers [@B17]. *LIN28B* functions by blocking the maturity of tumor-suppressing microRNA (miRNA) *let-7* family, which subsequently causes overexpression of numerous oncogenes, such as *C-MYC* and *K-RAS*, thereby supporting tumorigenesis and tumor growth [@B18],[@B19]. Meanwhile, *LIN28B* itself is downregulated by let-7, leading to the formation of double-negative feedback [@B20]. In this way, *LIN28B* is aberrantly expressed in a broad spectrum of tumors and engaged in the regulation of miRNAs [@B18],[@B20],[@B21]. A study showed that *LIN28B* is sufficient to drive liver tumors in the *let-7* miRNA dependent and independent ways in endogenous tumor models and is over-activated in mouse models of *MYC*-driven hepatoblastoma [@B19], which indicates its essential role in the development of hepatoblastoma.

The elucidation of genetic mechanisms of hepatoblastoma may accelerate the development of preventive oncology. Genome-wide association study (GWAS) is one of the emerging and promising techniques to associate genetic variations with disease risk. Most of the genetic variants are single nucleotide polymorphisms (SNPs). *LIN28B* polymorphisms were associated with Wilms tumor [@B22] and neuroblastoma [@B23] susceptibility in Chinese children. However, the relationship of *LIN28B* polymorphisms with hepatoblastoma susceptibility has not been investigated. In this study, we did a five-center case-control study to investigate the association between *LIN28B* gene polymorphisms and hepatoblastoma susceptibility in Chinese Han children.

Material and methods
====================

Patients and controls
---------------------

We enrolled 275 histopathologically diagnosed hepatoblastoma patients and 1018 cancer-free controls from Guangdong, Henan, Shaanxi, Yunnan and Liaoning provinces (**[Supplemental Table 1](#SM0){ref-type="supplementary-material"}**). All controls are unrelated to patients genetically. Moreover, controls were matched to patients by age, gender, and ethnicity. Our study was approved by the Ethics Committee of Guangzhou Women and Children\'s Medical Center. Written informed consent was obtained from each patient or his/her guardian. The study protocol was compliant with ethical guidelines.

SNP selection and genotyping
----------------------------

Four *LIN28B* polymorphisms (rs314276 C\>A, rs221634 A\>T, rs221635 T\>C and rs9404590 T\>G) were chosen and genotyped using the TaqMan real-time PCR method as we reported previously [@B22], [@B23]. Briefly, the selected polymorphisms were all potentially functional SNPs according to SNPinfo online software (<https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html>), which can affect the binding capacity of transcription factor binding sites (rs314276) or microRNA binding sites (rs221634 and rs221635), or leading to amino acids alterations (rs9404590). To validate the accuracy of genotyping results and for quality control, approximately 10% of the samples were randomly selected and re-genotyped. The concordance for the quality control samples was 100%.

Genotype and gene expression correlation analysis
-------------------------------------------------

GTEx Portal database (<https://www.gtexportal.org/home/>) was used to evaluate the correlation between genotypes of the selected polymorphisms and *LIN28B* mRNA expression levels [@B24].

Statistical analysis
--------------------

The χ^2^ test was used to evaluate the demographic variables distribution, risk factors distribution, and *LIN28B* genotype distributions between case and control groups. The χ^2^ test was also performed to assess whether or not the *LIN28B* genotypes were consistent with Hardy-Weinberg equilibrium (HWE). Unconditional univariate and multivariate logistic regression analyses were used to estimate the strength of association between the selected polymorphisms and hepatoblastoma risk, using odds ratio (ORs) and 95% confidence intervals (CIs). Age and gender were adjusted for in the multivariate analysis. Further stratification analysis was performed based on the age, sex, and clinical stages. Moreover, we also performed false-positive probability analysis (FPRP) analysis to verify the significant results from the combined subjects [@B25]. Differences with *P* values \<0.05 were counted as statistically significant. All two-sided statistical analyses were performed using SAS software (version 9.1; SAS Institute, Cary, NC, United States).

Results
=======

General characteristics of the subjects
---------------------------------------

As shown in **[Supplemental Table 1](#SM0){ref-type="supplementary-material"}**, there is no significant difference in both cases and controls in terms of age (*P*=0.365) and gender (*P*=0.589). The majority of the subjects in both cases and controls are male, accounting for 58.91% (162/275) and 60.71% (618/1018), respectively.

Association of *LIN28B* SNPs with hepatoblastoma susceptibility
---------------------------------------------------------------

Of the included subjects, 275 cases and 1017 controls were successfully genotyped. The *LIN28B* genotypes are in accordance with HWE in the controls (*P*=0.209 for rs314276 C\>A, *P*=0.969 for rs221634 A\>T, *P*=0.139 for rs221635 T\>C and *P*=0.868 for rs9404590 T\>G). The genotype frequencies of four SNPs in cases and controls were listed in **Table [1](#T1){ref-type="table"}**. Our results indicated that patients with the rs314276 A allele had higher cancer risk (AA vs. CC: adjusted OR=2.05, 95% CI=1.36-3.10, *P*=0.0006; AA vs. CA/CC: adjusted OR=2.11, 95% CI=1.43-3.12, *P*=0.0002). Carriers of the rs9404590 G allele also showed significantly increased risk (GG vs. TT: adjusted OR=1.89, 95% CI=1.20-3.00, *P*=0.007; GG vs. TT/TG: adjusted OR=1.87, 95% CI=1.20-2.92, *P*=0.006), compared with the reference group. According to the ORs, risk genotypes were carriers with rs314276 AA, rs221634 AA/AT, rs221635 TC/TT, rs9404590 TG/GG. Meanwhile, patients carrying four risk genotypes had a significantly elevated risk (adjusted OR=1.95, 95% CI=1.31-2.90, *P*=0.0009) when compared with those with 1-3 risk genotypes. Unfortunately, no significant association was detected for either rs221634 A\>T or rs221635 T\>C in any comparison.

Stratification analysis
-----------------------

As shown in **Table [2](#T2){ref-type="table"}**, we found a more prominent association for rs314276 AA genotype in the following subgroups: patients \<17 months (adjusted OR=2.19, 95% CI=1.28-3.76, *P*=0.005) and ≥17 months (adjusted OR=2.04, 95% CI=1.16-3.58, *P*=0.013), females (adjusted OR=2.21, 95% CI=1.20-4.06, *P*=0.011) and males (adjusted OR=2.04, 95% CI=1.23-3.39, *P*=0.006), as well as patients with tumors in clinical stages III+IV (adjusted OR=3.15, 95% CI=1.73-5.73, *P*=0.0002). The association between the rs9404590 GG genotype and increased cancer risk was more pronounced in the strata of patients ≥17 months (adjusted OR=2.02, 95% CI=1.07-3.83, *P*=0.031), females (adjusted OR=2.09, 95% CI=1.02-4.28, *P*=0.044) and patients with tumor in III+IV clinical stages (adjusted OR=2.88, 95% CI=1.47-5.62, *P*=0.002). As for risk genotypes, the association between 4 risk genotypes and HB risk was statistically significant in patients younger (adjusted OR=1.88, 95% CI=1.08-3.29, *P*=0.027) and ≥17 months (adjusted OR=2.04, 95% CI=1.16-3.58, *P*=0.013), males (adjusted OR=1.94, 95% CI=1.03-3.63, *P*=0.039), and females (adjusted OR=1.95, 95% CI=1.17-3.25, *P*=0.010) and patients with tumor in III+IV clinical stages (adjusted OR=3.15, 95% CI=1.73-5.73, *P*=0.0002).

Genotype-based mRNA expression analysis
---------------------------------------

We found that the rs9404590 T\>G polymorphism was significantly associated with altered gene expression in transformed fibroblast cells using data from the GTEx Portal (*P*=2.20\*10^-4^, **Figure [1](#F1){ref-type="fig"}**).

False-positive report probability results
-----------------------------------------

We preset 0.2 as the FPRP threshold. As shown in**Table [3](#T3){ref-type="table"}**, at the prior probability of 0.1, the significant findings for the rs314276 C\>A polymorphism remained noteworthy on the rs314276 AA genotype (FPRP=0.064), recessive model (FPRP=0.037) and the III+IV stage tumor (FPRP=0.144). All of the significant finding in rs9404590 T\>G disappeared. Moreover, in the combined analysis, results with 4 risk genotypes remained noteworthy when compared with results with a risk genotype (FPRP=0.052) and 1-3 genotypes (FPRP=0.078), and in the stratified analysis, results of stage III+IV tumors also reached FPRP threshold (FPRP=0.144).

Discussion
==========

In this case-control study, we investigated the association between *LIN28B* SNPs with the risk of hepatoblastoma in Chinese children. To the best of our knowledge, our team is the first group to assess the association of *LIN28B* SNPs with hepatoblastoma susceptibility.

The*LIN28B* gene is located on chromosome 6q21 and encodes a miRNA-binding protein [@B26]. The heterochronic *LIN28* gene the in *Caenorhabditis elegans* [@B27], and its mammalian homologue *LIN28B* gene is complementary to*lin-4* homologues miR-125 and *let-7* critical by the segment of the unusually long 3\' untranslated region (UTR) in diverse mammalian tissues [@B17], [@B27]-[@B29]. In this way, *LIN28B* sustains the proliferative and metabolic capacities of pluripotent stem cells and facilitates the transition of them from naive to primed pluripotency [@B17], [@B30]-[@B32]. Since *LIN28B* functions as a key regulator in the diverse developing events, SNPs in the 3\' UTR may play important roles. SNPs in this gene have been extensively explored concerning the regulation of secondary sexual characteristics and tumorigenesis. For example, *LIN28B* rs314276 C\>A polymorphism has been shown to associate with reproductive timing [@B33],[@B34], central precocious puberty [@B35], the linkage between puberty timing and adult disease [@B36], and the finger-length ratio [@B37]. Meanwhile, this variant was also found to be associated with the risk and survival of cancers, such as Wilms tumor [@B22], neuroblastoma [@B23] and epithelial ovarian cancer [@B38]. Previous data also showed that *LIN28B* rs221634 A\>T, rs221635 T\>C, and rs9404590 T\>G were related to the susceptibility to Wilms tumor [@B22] and neuroblastoma [@B23].

The *LIN28B* is upregulated to repress the function of the tumor suppressor miRNA *let-7* family in the diverse tumor types and serve as a regulator of miRNA [@B20],[@B39]-[@B41]. The overexpression of *LIN28B* can lead to the activation of several oncogenes [@B42]. In the previous study, miR-100, let-7a, and the *Caenorhabditis elegans lin-4* orthologue miR-125b are sharply downregulated in the hepatoblastoma [@B43]. It is noteworthy that two of the miRNAs (miR-125b and let-7a) in the cluster are *LIN28B*-related miRNA [@B27], indicating a potential molecular mechanism. Meanwhile, *LIN28B* and *AURKA* expressions were upregulated in a transcriptomic and genomic analysis of human hepatoblastoma, and miRNA-26-5p inhibited hepatoblastoma by repressing *LIN28B* [@B44].*LIN28B* might also increase the risk of hepatoblastoma through LIN28B-RAN-AURKA pathway [@B44]. The previous study showed that *LIN28B* is an oncofetal cancer stem cell-like marker in the recurrence of hepatocellular carcinoma [@B45]. Hepatocellular carcinoma may have similar molecular mechanisms with hepatoblastoma, such as the activation of the Wnt/β-catenin signaling pathway [@B46]-[@B49]. Therefore, it was reasonable to investigate the genetic implication of the *LIN28B* gene in the risk of hepatoblastoma.

Despite the findings that*LIN28B* rs94904590 T\>G and rs314276 C\>A could increase hepatoblastoma risk, the study suffered from some minor limitations. First, we did not find the exact molecular mechanism underlying the established associations in the study. Secondly, the sample size might be small to conclude, partly due to the low incidence rate of the disease. Validation experiments are needed in the future. Thirdly, we only recruited the Han Chinese people in our study. Fourthly, we only included four potentially functional SNPs in the *LIN28B* gene, other SNPs including the ones without functional were not included in the current study. Finally, functional experiments should be performed to further explore the role of *LIN28B* in the carcinogenesis of hepatoblastoma.

In all, our study demonstrated that *LIN28B* rs94904590 T\>G and rs314276 C\>A might confer increased hepatoblastoma risk in Chinese children. In the future, studies with a larger sample size are called to clarify the impact of *LIN28B* SNPs on the risk of hepatoblastoma.
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Association between *LIN28B* gene polymorphisms and hepatoblastoma susceptibility

  Genotype                                Cases (N=275)   Controls (N=1017)   *P*^a^   Crude OR (95% CI)      *P*          Adjusted OR (95% CI) ^b^   *P*^b^
  --------------------------------------- --------------- ------------------- -------- ---------------------- ------------ -------------------------- ------------
  **rs314276 (HWE=0.209)**                                                                                                                            
  CC                                      123 (44.73)     483 (47.49)                  1.00                                1.00                       
  CA                                      107 (38.91)     448 (44.05)                  0.94 (0.70-1.25)       0.664        0.94 (0.70-1.26)           0.672
  AA                                      45 (16.36)      86 (8.46)                    **2.06 (1.36-3.10)**   **0.0006**   **2.05 (1.36-3.10)**       **0.0006**
  Additive                                                                    0.017    **1.27 (1.04-1.55)**   **0.018**    **1.27 (1.04-1.55)**       **0.018**
  Dominant                                152 (55.27)     534 (52.51)         0.415    1.12 (0.86-1.46)       0.415        1.12 (0.86-1.46)           0.409
  Recessive                               230 (83.64)     931 (91.54)         0.0001   **2.12 (1.44-3.12)**   **0.0002**   **2.11 (1.43-3.12)**       **0.0002**
  **rs221634 (HWE=0.969)**                                                                                                                            
  AA                                      94 (34.55)      342 (33.63)                  1.00                                1.00                       
  AT                                      144 (52.36)     495 (48.67)                  1.05 (0.78-1.40)       0.758        1.04 (0.78-1.40)           0.772
  TT                                      36 (13.09)      180 (17.70)                  0.72 (0.47-1.10)       0.129        0.72 (0.47-1.10)           0.130
  Additive                                                                    0.239    0.89 (0.73-1.08)       0.239        0.89 (0.73-1.08)           0.239
  Dominant                                180 (65.45)     675 (66.37)         0.776    0.96 (0.73-1.27)       0.775        0.96 (0.72-1.27)           0.765
  Recessive                               239 (86.91)     837 (82.30)         0.069    0.70 (0.48-1.03)       0.071        0.70 (0.48-1.03)           0.073
  **rs221635 (HWE=0.139)**                                                                                                                            
  TT                                      185 (67.27)     652 (64.11)                  1.00                                1.00                       
  TC                                      79 (28.73)      315 (30.97)                  0.88 (0.66-1.19)       0.413        0.88 (0.66-1.19)           0.407
  CC                                      11 (4.00)       50 (4.92)                    0.78 (0.40-1.52)       0.459        0.78 (0.40-1.52)           0.458
  Additive                                                                    0.300    0.88 (0.70-1.12)       0.300        0.88 (0.70-1.12)           0.296
  Dominant                                90 (32.73)      365 (35.89)         0.330    0.87 (0.66-1.15)       0.330        0.87 (0.65-1.15)           0.325
  Recessive                               264 (96.00)     967 (95.08)         0.525    0.81 (0.41-1.57)       0.526        0.81 (0.41-1.57)           0.527
  **rs9404590 (HWE=0.868)**                                                                                                                           
  TT                                      141 (51.27)     558 (54.87)                  1.00                                1.00                       
  TG                                      102 (37.09)     392 (38.54)                  1.03 (0.77-1.37)       0.841        1.03 (0.78-1.37)           0.834
  GG                                      32 (11.64)      67 (6.59)                    **1.89 (1.19-2.99)**   **0.007**    **1.89 (1.20-3.00)**       **0.007**
  Additive                                                                    0.045    **1.23 (1.00-1.51)**   **0.045**    **1.24 (1.01-1.52)**       **0.044**
  Dominant                                134 (48.73)     459 (45.13)         0.289    1.16 (0.89-1.51)       0.289        1.16 (0.89-1.51)           0.284
  Recessive                               243 (88.36)     950 (93.41)         0.005    **1.87 (1.20-2.91)**   **0.006**    **1.87 (1.20-2.92)**       **0.006**
  **Combined effect of risk genotypes**                                                                                                               
  1                                       44 (16.00)      219 (21.53)                  1.00                                1.00                       
  2                                       97 (35.27)      350 (34.41)                  1.38 (0.93-2.05)       0.100        1.37 (0.93-2.04)           0.115
  3                                       92 (33.45)      362 (35.59)                  1.27 (0.85-1.88)       0.245        1.26 (0.85-1.88)           0.249
  4                                       42 (15.27)      86 (8.46)                    **2.43 (1.49-3.97)**   **0.0004**   **2.43 (1.48-3.96)**       **0.0004**
  1-3                                     233 (84.73)     931 (91.54)                  1.00                                1.00                       
  4                                       42 (15.27)      86 (8.46)           0.0008   **1.95 (1.31-2.90)**   **0.0009**   **1.95 (1.31-2.90)**       **0.0009**

OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium. ^a^ χ^2^ test for genotype distributions between hepatoblastoma patients and controls, ^b^ Adjusted for age and gender, ^c^ Risk genotypes were carriers with rs314276 AA, rs221634 AA/AT, rs221635 TC/TT, rs9404590 TG/GG.

###### 

Stratification analysis of*LIN28B* risk genotypes with hepatoblastoma susceptibility

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables         rs314276\          AOR (95% CI) ^a^   *P* ^a^                rs9404590\         AOR (95% CI) ^a^   *P* ^a^   Combined\              AOR (95% CI) ^a^   *P* ^a^                                  
                    (cases/controls)                                             (cases/controls)                                (cases/controls)                                                                   
  ----------------- ------------------ ------------------ ---------------------- ------------------ ------------------ --------- ---------------------- ------------------ --------- ------- ---------------------- ------------
                    CC/CA              AA                                                           TT/TG              GG                                                  1-3       4                              

  Age, month                                                                                                                                                                                                        

  \<17              123/420            25/39              **2.19 (1.28-3.76)**   **0.005**          131/427            17/32     1.73 (0.93-3.21)       0.084              126/420   22/39   **1.88 (1.08-3.29)**   **0.027**

  ≥17               107/511            20/47              **2.04 (1.16-3.58)**   **0.013**          112/523            15/35     **2.02 (1.07-3.83)**   **0.031**          107/511   20/47   **2.04 (1.16-3.58)**   **0.013**

  Gender                                                                                                                                                                                                            

  Females           94/366             19/33              **2.21 (1.20-4.06)**   **0.011**          100/376            13/23     **2.09 (1.02-4.28)**   **0.044**          96/366    17/33   **1.94 (1.03-3.63)**   **0.039**

  Males             136/565            26/53              **2.04 (1.23-3.39)**   **0.006**          143/574            19/44     1.74 (0.98-3.07)       0.057              137/565   25/53   **1.95 (1.17-3.25)**   **0.010**

  Clinical stages                                                                                                                                                                                                   

  I+II              124/931            18/86              1.57 (0.92-2.70)       0.101              129/950            13/67     1.44 (0.78-2.69)       0.247              125/931   17/86   1.48 (0.85-2.56)       0.168

  III+IV            55/931             16/86              **3.15 (1.73-5.73)**   **0.0002**         59/950             12/67     **2.88 (1.47-5.62)**   **0.002**          55/931    16/86   **3.15 (1.73-5.73)**   **0.0002**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AOR, adjusted odds ratio; CI, confidence interval. ^a^ Adjusted for age and gender, omitting the corresponding factor.

###### 

False-positive report probability analysis for significant findings

  --------------------------------------------------------------------------------------------------------------------
  Genotype         OR (95% CI)        *P* ^a^   Statistical\   Prior probability                               
                                                power ^b^                                                      
  ---------------- ------------------ --------- -------------- ------------------- ----------- ------- ------- -------
  rs314276 C\>A                                                                                                

  AA vs. CC        2.06 (1.36-3.10)   0.0006    0.079          **0.022**           **0.064**   0.429   0.883   0.987

  AA vs. CC/CA     2.12 (1.44-3.12)   0.0002    0.047          **0.013**           **0.037**   0.296   0.809   0.977

  \<17 month       2.19 (1.27-3.76)   0.005     0.085          **0.137**           0.324       0.840   0.982   0.998

  ≥17 month        2.03 (1.16-3.57)   0.014     0.147          0.217               0.454       0.902   0.989   0.999

  Females          2.24 (1.22-4.12)   0.009     0.098          0.221               0.460       0.903   0.990   0.999

  Males            2.04 (1.23-3.38)   0.006     0.117          **0.127**           0.304       0.828   0.980   0.998

  Stage III+IV     3.15 (1.73-5.73)   0.0002    0.011          **0.053**           **0.144**   0.649   0.949   0.995

  rs9404590 T\>G                                                                                               

  GG vs. TT        1.89 (1.19-2.99)   0.007     0.177          **0.102**           0.254       0.789   0.974   0.997

  GG vs. GT/TT     1.87 (1.20-2.91)   0.006     0.168          **0.095**           0.240       0.777   0.972   0.997

  ≥17 month        2.00 (1.06-3.79)   0.033     0.190          0.344               0.612       0.945   0.994   0.999

  Females          2.13 (1.04-4.34)   0.039     0.170          0.406               0.673       0.958   0.996   1.000

  Stage III+IV     2.88 (1.48-5.63)   0.002     0.032          **0.150**           0.346       0.853   0.983   0.998

  Risk genotypes                                                                                               

  4 vs. 1          2.43 (1.49-3.97)   0.0004    0.065          **0.018**           **0.052**   0.377   0.859   0.984

  4 vs. 1-3        1.95 (1.31-2.90)   0.0009    0.095          **0.028**           **0.078**   0.484   0.904   0.990

  \<17 month       1.88 (1.08-3.29)   0.027     0.213          0.274               0.532       0.926   0.992   0.999

  ≥17 month        2.03 (1.16-3.57)   0.014     0.147          0.217               0.454       0.902   0.989   0.999

  Females          1.96 (1.05-3.68)   0.035     0.200          0.343               0.611       0.945   0.994   0.999

  Males            1.95 (1.17-3.24)   0.011     0.160          **0.167**           0.376       0.869   0.985   0.999

  Stage III+IV     3.15 (1.73-5.73)   0.0002    0.011          **0.053**           **0.144**   0.649   0.949   0.995
  --------------------------------------------------------------------------------------------------------------------

OR, odds ratio; CI, confidence interval.

^a^Chi-square test was used to calculate the genotype frequency distributions, ^b^Statistical power was calculated using the number of observations in each subgroup and the corresponding ORs and *P* values in this table.
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